Does open label extension trials impact patients to enroll in clinical trials?

被引：0
|
作者：
Hank, Nicole C. [1 ]
Chung, Steve S. [1 ]
机构：
[1] Barrow Neurol Inst, Phoenix, AZ 85013 USA
来源：
EPILEPSIA | 2006年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：252 / 252
页数：1
相关论文
共 50 条
  • [21] Influence of demographics on patient refusal to enroll into clinical trials.
    Midathada, MV
    Spencer, T
    Mack, K
    Erkman, L
    Govindarajan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 537S - 537S
  • [22] Safety And Tolerability Of Nintedanib In Patients With Ipf: Interim Analysis From An Open-Label Extension Of The Inpulsis® Trials (inpulsis®-On)
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Quaresma, M.
    Coeck, C.
    Kaye, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [23] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
  • [24] Safety of adalimumab maintenance therapy in crohn's disease patients: open-label extension of charm and gain trials
    Colombel, J. F.
    Rutgeerts, P.
    Sandborn, W. J.
    Panaccione, R.
    Lau, W.
    Lomax, K. G.
    Pollack, P. F.
    GUT, 2008, 57 : A49 - A49
  • [25] INTERIM ANALYSIS OF NINTEDANIB IN AN OPEN-LABEL EXTENSION OF THE INPULSIS (R) TRIALS (INPULSIS (R)-ON)
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Coeck, C.
    Quaresma, M.
    Kreuter, M.
    Kaye, M.
    THORAX, 2015, 70 : A77 - A78
  • [26] Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials
    Lord-Bessen, Jennifer
    Signorovitch, James
    Yang, Min
    Georgieva, Mihaela
    Roydhouse, Jessica
    JNCI CANCER SPECTRUM, 2023, 7 (02)
  • [27] Considerations for open-label randomized clinical trials: Design, conduct, and analysis
    Higgins, Karen M.
    Levin, Gregory
    Busch, Robert
    CLINICAL TRIALS, 2024,
  • [28] Clinical, technical, and social contingencies and the decisions of adults with HIV/AIDS to enroll in clinical trials
    Mueller, MR
    QUALITATIVE HEALTH RESEARCH, 2004, 14 (05) : 704 - 713
  • [29] Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials
    Anzelewicz, Stefan
    Garnier, Hanna
    Rangaswami, Arun
    Czauderna, Piotr
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (08): : 613 - 621
  • [30] Trials of stem cell therapy in heart failure enroll first patients
    不详
    REGENERATIVE MEDICINE, 2009, 4 (05) : 643 - 643
12345